RxDoctor Payments Data

Sukhjeet Singh, DO

Cardiovascular Disease · Mount Arlington, NJNPI 1851690200

Payments from drug & device makers

$7,166in general payments, 2019–2025

Across 474 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$978
  • Novo Nordisk$677
  • Johnson & Johnson$650
  • Boehringer Ingelheim$502
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$419
  • AstraZeneca$413
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$7,146100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,166 in reported general payments places this provider in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$341,666
Medicare patients
2,214
Services billed
5,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban329$383,702
MounjaroTirzepatide141$161,137
OzempicSemaglutide99$131,735
XareltoRivaroxaban89$98,377
JardianceEmpagliflozin56$57,844
EntrestoSacubitril/Valsartan40$57,176
MultaqDronedarone Hcl28$46,648
FarxigaDapagliflozin Propanediol38$41,429
WegovySemaglutide18$28,298
Repatha SureclickEvolocumab15$11,099
Metoprolol Succinate539$7,293
Atorvastatin Calcium523$4,902
Valsartan136$3,470
Ranolazine ErRanolazine35$3,190
Rosuvastatin Calcium257$2,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$292$383,702329 claims
Lilly USA, LLCMounjaro$265$161,137141 claims
Novo NordiskOzempic, Wegovy$677$160,034117 claims
Johnson & JohnsonXarelto$650$98,37789 claims
Boehringer IngelheimJardiance$502$57,84456 claims
NovartisEntresto$978$57,17640 claims
Sanofi-aventis U.S. LLCMultaq$159$46,64828 claims
AstraZenecaFarxiga$413$41,42938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Mount Arlington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →